Literature DB >> 30969083

Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.

Qin Wang, Yuanyuan Wu, Hao Zhang, Kai Yang, Yang Tong, Liwen Chen, Qiang Zhou, Shihe Guan.   

Abstract

BACKGROUND: Ovarian cancer is one of the most common cancers among women. With cancer, early detection is paramount to saving lives. However, early detection of ovarian cancer has been fraught with difficulty. The diagnostic performance of HE4, CA125, ROMA index, and CA72-4 was evaluated for ovarian cancer.
METHODS: This was a diagnostic study enrolling 97 patients with pelvic masses who had been scheduled for surgery and 33 healthy women. Serum levels of tumor markers, including human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), and carbohydrate antigen 72-4 (CA72-4) were detected in each patient and analyzed using the risk of ovarian malignancy algorithm (ROMA) index for sensitivity, specificity, positive predictive values, negative predictive values, and accuracy. ROC curve analysis was conducted to compare the diagnostic performances of serum HE4, CA125, CA72-4, and ROMA index in ovarian cancer. The dynamic changes of these biomarkers were analyzed in patients with ovarian cancer after operation.
RESULTS: HE4 had the best specificity, CA72-4 had the lowest sensitivity, and ROMA index had the best diagnostic efficiency among these biomarkers for diagnosis of ovarian cancer. CA125 had better specificity in the post-menopausal group than in non-menopausal group. The kinetic changes of HE4, CA125, and ROMA index in patients with ovarian cancer were consistent with the remission and recurrence of the disease.
CONCLUSIONS: HE4 and ROMA index which reference intervals are established according to the menopausal status have important clinical significance in the diagnosis of ovarian cancer. Regular detection of serum HE4, CA125, and ROMA index can help predict postoperative recurrence of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30969083     DOI: 10.7754/Clin.Lab.2018.181030

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

Review 1.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

2.  MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.

Authors:  Haoya Xu; Ruoyao Zou; Feifei Li; Jiyu Liu; Nannan Luan; Shengke Wang; Liancheng Zhu
Journal:  Cancer Med       Date:  2021-05-02       Impact factor: 4.452

3.  Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.

Authors:  Li-Yuan Feng; Sheng-Bin Liao; Li Li
Journal:  J Ovarian Res       Date:  2020-02-12       Impact factor: 4.234

4.  Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.

Authors:  Zengbao Lin; Huiqin Bian; Chaoyuan Chen; Wenling Chen; Qiong Li
Journal:  J Gastrointest Oncol       Date:  2021-06

5.  Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.

Authors:  Li-Yuan Feng; Bing-Bing Yan; Yong-Zhi Huang; Li Li
Journal:  Clin Epigenetics       Date:  2021-07-21       Impact factor: 6.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.